# ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS

> **NCT01709396** · PHASE2 · SUSPENDED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 20 (estimated)

## Conditions studied

- Acute Leukemia
- Myelodysplastic Syndrome

## Interventions

- **RADIATION:** ED-TBI

## Key facts

- **NCT ID:** NCT01709396
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2012-01
- **Primary completion:** 2016-01
- **Final completion:** 2018-01
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** initial on hold due to space but now permanently suspended due to futility.
- **Last updated:** 2017-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709396, "ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01709396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*